Recent Company News

• 08:02 AM ET Sep 22, 2026
  

  Rhythm Pharmaceuticals announces Health Canada approves IMCIVREE for weight management in adult and pediatric patients 4 years of age and older with acquired hypothalamic obesity ($98.83, 0.00)

• 08:42 AM ET Sep 21, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 04:13 AM ET Sep 21, 2026
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 02:41 AM ET Sep 21, 2026
  

  StreetAccount Summary - European pre-market trading update

• 04:03 PM ET Sep 18, 2026
  

  Amneal Pharmaceuticals announces FDA approval and launch of lanreotide injection ($18.71, 0.00)

• 09:22 AM ET Sep 14, 2026
  

  Biomunex (private) announces milestone payment from Ipsen triggered by IND clearance for bispecific IPN60330 (8:35ET) (€158.60, +1.50)

• 08:05 AM ET Sep 10, 2026
  

  Rhythm Pharmaceuticals announces new data presentations at the European Society for Paediatric Endocrinology Meeting ($101.06, 0.00)

• 04:30 PM ET Sep 08, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 01:02 AM ET Aug 21, 2026
  

  Ipsen completes acquisition of Kartos Therapeutics; deal was announced 29-Jun (€163.40, 0.00)

• 06:13 AM ET Aug 20, 2026
  

  China's NMPA to include Ipsen's Iqirvo in priority review list for adults who do not respond well to UDCA alone, or used by itself for patients who cannot tolerate UDCA (€165.30, +0.20)